Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
letrozole + anastrozole + exemestane + fulvestrant + leuprorelin + goserelin
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
This combination refers to a protocol-specified set of endocrine therapy (ET) agents used in a Phase II clinical trial led by Fudan University for the maintenance treatment of HER2-positive advanced breast cancer. The regimen includes aromatase inhibitors (letrozole, anastrozole, and exemestane), a selective estrogen receptor degrader (fulvestrant), and gonadotropin-releasing hormone (GnRH) agonists (leuprorelin and goserelin). These agents are administered following induction therapy with the antibody-drug conjugate trastuzumab rezetecan (SHR-A1811) and are combined with other targeted therapies like pyrotinib or dalpiciclib. The primary goal of this endocrine component is to suppress estrogen signaling in patients with hormone receptor-positive (HR+) disease, either by blocking estrogen production or by antagonizing the estrogen receptor itself.
- Other names
- Endocrine TherapyET
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)ESR1 (ERα)ESR2 (ERβ)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on letrozole + anastrozole + exemestane + fulvestrant + leuprorelin + goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on letrozole + anastrozole + exemestane + fulvestrant + leuprorelin + goserelin.